I am the Director of CRUK Barts Centre. My groups' primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun (2017) 9;8(1):1395. PMID: 29123084
Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. Gene Ther (2015) 22: 476-484. PMID: 25876464
A Vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin Cancer Res (2015) 21: 405-416. PMID: 25416195
A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med (2014) 6:105. PMID: 25587357
I work with Professor Claude Chelala and Dr Tatjana Crnogorac-Jurcevic on the genomics and molecular pathology of pancreatic cancer. We use global profiling approaches at the genomic and proteomic levels to identify targets that can be exploited for detection and treatment of this disease. We are also developing novel platforms and algorithms for the bioinformatic interrogation and interpretation of very large, multidimensional datasets.
I work with Professor Yaohe Wang and Dr Gunnel Halldén on the development of oncolytic virotherapy, an approach that uses adenoviruses and vaccinia viruses that selectively replicate within and kill cancer cells, but leave normal cells untouched. We are also working on defining the cell survival signalling circuits that determine the sensitivity of cancer cells to this approach. The role of the immune system in modulating viral replication and tumour cell destruction is the focus of a major new programme.
National and International Committees (current)
External scientific activities
SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. Dayem Ullah AZ, Oscanoa J, Wang J et al. Nucleic Acids Res (2018) 46(2) W109-W113
TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Ottaviani S, Stebbing J, Frampton AE et al. Nat Commun (2018) 9(2) 1845
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Marelli G, Howells A, Lemoine NR et al. Frontiers in Immunology (2018) 9(1) 866-866
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Wang P, Li X, Wang J et al. Nat Commun (2018) 9(2) 203
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Wang P, Li X, Wang J et al. Nat Commun (2017) 8(1) 1395-1395
The Pancreatic Expression Database: 2018 update. Marzec J, Dayem Ullah AZ, Pirrò S et al. Nucleic Acids Res (2017) 46(1) D1107-D1110
Correction for Spurrell et al., "STAT1 Interaction with E3-14.7K in Monocytes Affects the Efficacy of Oncolytic Adenovirus". Spurrell E, Gangeswaran R, Wang P et al. J Virol (2017) 91(2)
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Howells A, Marelli G, Lemoine NR et al. Front Oncol (2017) 7(1) 195-195
Gene therapy-from small beginnings to where we are now. Glorioso JC, Lemoine N Gene Ther (2017) 24(2) 495-496
'Multi-omic' data analysis using O-miner. Sangaralingam A, Dayem Ullah AZ, Marzec J et al. Brief Bioinform (2017) (1)
I trained in medicine at St Bartholomew's Hospital Medical College where I qualified with the University of London Gold Medal in 1983, specialising in pathology and oncology with posts in London and Cardiff. I gained my PhD in molecular oncology in 1988 working on the molecular genetics of thyroid cancer at The University of Wales College of Medicine in Cardiff, and then my MD in molecular oncology in 1992 working on growth factor receptor abnormalities at the Royal Postgraduate Medical School, London.
I was Professor of Molecular Pathology at Imperial College London, where I was Director of the Cancer Research UK Molecular Oncology Unit and the first Director of the National Translational Cancer Research Centre at Hammersmith Hospital, before moving to become Director of the Barts Cancer Institute in 2005.
I am currently Chair of Trustees of the Medical Research Foundation (MRC’s independent charity), and Chair of funding and research strategy boards including the NIHR i4i Challenge Awards Panel, Diabetes UK Research Committee, Prostate Cancer UK Research Strategy Board, Pancreatic Cancer Research Fund Scientific Committee, Irish Health Board & Research Charities Committee. I am also a member of the MRC Stratified Medicine Expert Review Committee (Vice Chair), CR-UK Clinical Research Monitoring Committee, Pancreatic Cancer UK Scientific Advisory Committee, and the Lister Institute for Preventive Medicine.
I have previously been Chairman of the MRC Clinical Research & Career Development Panel and the NIHR Clinician Scientist Appointments & Review Panel. I chaired the MRC Stem Cell Fellowship Panel, the CR-UK Clinician Scientist and Senior Clinician Fellowship Panel and the MRC Experimental Medicine Review Panel for the Molecular & Cellular Medicine Board. I was a long-serving member of the Gene Therapy Advisory Committee at the Department of Health, as well as the CR-UK Science Funding Committee, MRC Molecular & Cellular Medicine Board, CORE Scientific Advisory Board and many other scientific review committees.
I was the Editor of the Nature Specialist Journal Gene Therapy for twenty years (1997- 2017), and my research into the molecular genetics of cancer and gene therapy has been funded by programme grants from MRC, Cancer Research UK, Digestive Cancer Campaign and the European Union. I was elected as a fellow of the Academy of Medical Sciences in 2006 and as a Foreign Academician of the Chinese Academy of Engineering in 2017. I was presented with the China National Friendship Award by Premier Li Keqiang of the Chinese Government in 2017.